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Modulation oftransforming growth factor beta expression and induction of
apoptosis by tamoxifen in ER positive and ER negative breast cancer cells
Sir - We read with interest the paper by Perry et al. (1995)
reporting pharmacological modulation of transforming
growth factor P1 (TGF-fli) expression in MCF-7 cells by
mechanisms that appear to be independent of the conven-
tional oestrogen receptor (ER) and that may involve either
transcriptional or post-transcnrptional events.
Our group have previously reported induction of this
potent epithelial growth inhibitor by tamoxifen in fetal
fibroblasts in vitro and proposed a negative paracrine
hypothesis (Colletta et al.. 1990). Consistent wAith this
concept of a direct action of tamoxifen upon fibroblasts. we
subsequently demonstrated stromal induction of TGF-13, in
both ER-positive and ER-negative breast cancers follow%ing
primary tamoxifen therapy (Butta et al.. 1992). Up-regulation
was seen prodominantly between and around stromal
fibroblasts. with little increased immunoreactivity in the
vicinity of epithelial cells. In this respect, these results were
at variance with previous in vitro studies showing induction
ofTGF-,B by tamoxifen in MCF-7 cells (Knabbe et al.. 1987).
The present study concurs with the latter observations and
supports the existence of both functional autocrine and
paracrine inhibitory loops involving TGF-f3, (Benson and
Colletta. 1995). However. previous work on induction of
TGF-fl, in breast carcinoma cell lines revealed that this
response to anti-oestrogens was confined to ER-positive
(MCF-7) cells. and growth inhibition of ER-negative cells
was only observed when these were co-cultured in the
presence of MCF-7 cells, which alone could respond to
tamoxifen and produce TGF-fl. which acted in a negative
paracrine manner upon ER-negative cells (Knabbe et al..
1987). These results were consistent with tamoxifen acting via
the ER with TGF-fl, being a proximate growth modulator.
We have recently confirmed induction of TGF-fl, in the
breast tumour fibroblasts in vitro in the absence of any
detectable ER protein (Benson et al.. 1995). The modulation
of TGF-J, expression in both ER-positive and ER-negative
breast cancer cells observed in the present study may reflect a
common ER-independent mechanism of action that is
operative in both epithelial cells and fibroblasts.
However, it should be noted that the concentrations of
tamoxifen employed in this study were relatively high. In our
own in vitro experiments. maximal induction was observed at
tamoxifen concentrations of between 500 and 1000 nm. and
similar concentrations induced TGF-13, in MCF-7 cells. A
biphasic pattern of growth inhibition of breast cancer cells by
anti-oestrogens has been observed. with an E2 reversible
effect at concentrations of 10-1000 nm. and an E2
irreversible inhibition at concentrations of 1-10 pm (Suther-
land et al.. 1986). Although specific non-ER-mediated
mechanisms cannot be excluded. it is possible that growth
inhibition at higher concentrations represents a direct
cytotoxic action of tamoxifen upon cells. Indeed. Bronzert
et al. (1985) reported the maximal non-cytotoxic growth-
inhibitory doses of anti-oestrogens to be <1 pm for MCF-7
cells.
These considerations raise the issue of whether the
concentrations of tamoxifen used in the present study exert
non-specific cytotoxic effects rather than formally activating
pathways leading to enhanced TGF-f production. Pro-
grammed cell death could result from such non-specific
action. and indeed may be a final common pathway for many
cytotoxic agents. Any apparent increases in cytosolic TGF-f31
protein could be a consequence of defective secretion with
intracellular retention secondarv to cytotoxic effects of
tamoxifen. It is noteworthy that the induction of TGF-,B
was relatively modest. with 2-3 times probably being the
minimal fold induction with physiological consequence.
Much greater magnitudes of induction have been witnessed
in vitro (Colletta et al.. 1990: Benson et al.. 1995) and in vivo
(Butta et al.. 1992).
The suggestion that tamoxifen may act by a post-
transcriptional mechanism at lower concentrations and a
transcriptional one at higher concentrations of anti-oestrogen
is intriguing: we have confirmed that induction of TGF-fl, in
breast tumour fibroblasts is not associated with elevated
levels of transcript. Moreover. tamoxifen may enhance rates
of translation by overcoming the inhibitory influence of stem-
loop structures in the long 5' untranslated region of TGF-fl
mRNA (Kim et al.. 1992). Such structures may interfere with
ribosomal binding directly or via a cytoplasmic protein that
could be displaced by tamoxifen. This mechanism may
become saturated at higher concentrations of tamoxifen.
when increased levels of TGF-f31 mRNA must precede
augmentation of protein production. Several studies have
suggested that modulation of TGF-# isoforms in vivo in
response to tamoxifen occurs at the transcriptional level
(Thompson et al.. 1991: MacCullum et al.. 1994). Perhaps
dual mechanisms are operative depending upon the nuances
of pharmacokinetics and the precise concentrations of
tamoxifen in the immediate cellular environment.
JR Benson.
M Baum.
Academic Department of Surgery.
The Royal Marsden Hospital.
Fulham Road.
London SW3 6JJ
UK
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Association ofTGF-f)1 expression with the effects oftamoxifen on estrogen
receptor positive and negative breast cancer cells
Sir - We thank Dr Benson and Dr Baum for their comments
regarding our paper (Perry et al., l995a). We are familiar
with their studies on the potential role of transforming
growth factor (TGF)-f3, produced by stromal fibroblasts in
tamoxifen-induced growth inhibition. As our work, and the
work of others (Knabbe et al., 1987), indicates that tamoxifen
has direct effects on epithelial cells, we agree that tamoxifen
may act via both functional autocrine and paracrine
inhibitory loops involving TGF-fl. The relative importance
of autocrine and or paracnine TGF-fl, secretion in tamoxifen-
induced growth inhibition may be dependent on the cell line
and the dose and duration of tamoxifen treatment.
Knabbe et al. (1987) have shown that oestrogen receptor
(ER)-positive MCF-7 cells respond to anti-oestrogen (100 nm
4-hydroxytamoxifen), but ER-negative MDA-231 cells do
not. However, other studies have shown that ER-negative
cells, including MDA-231, respond to tamoxifen concentra-
tions of I pum or greater (Taylor et al., 1984). We have also
noted that. although MCF-7 cells are more sensitive to
tamoxifen than MDA-231 cells, MDA-231 cells do respond
to micromolar concentrations of tamoxifen (Perry et al..
1995b). The response of ER-negative cells to tamoxifen is not
surprising as several clinical studies have shown that the
effectiveness of tamoxifen is independent of ER status (for
review see Jaiyesimi et al.. 1995). As we were interested in
studying the potential role of TGF-f, in ER-negative as well
as ER-positive cells. we chose a concentration of tamoxifen
(10 pm) that possessed significant activity against both cell
lines. Although this tamoxifen concentration is relatively high
compared with the serum levels achieved in patients on
standard dose (20-80 mg day-1) therapy, anti-oestrogens
accumulate in human tissues and tumours at levels 10-60
times higher than in serum (Lien et al.. 1991). Thus.
intratumoral tamoxifen concentrations may be in the
micromolar range. We agree that a 10 um tamoxifen
concentration is likely in a range in which the effects are
no longer solely dependent on ER. Indeed. this is supported
by our results. whereby 10 pm tamoxifen had similar effects
on TGF-fi, expression in both the ER-positive MCF-7 and
ER-negative MDA-231 cell lines. Also, the addition of
oestrogen failed to inhibit tamoxifen-induced TGF-fl1
expression in either cell line, again indicating that tamoxifen
at this concentration appears to induce TGF-fl1 through an
ER-independent mechanism. We concur with the conclusions
of Taylor et al. (1984) and Sutherland et al. (1986), that
tamoxifen appears to have both ER- and non-ER-dependent
activity.
Many, if not all. cytotoxic agents are capable of inducing
programmed cell death (apoptosis). This includes agents with
different mechanisms of action and that cause damage to
different targets. However, we do not agree with Dr Benson
and Dr Baum that the apoptotic activity of tamoxifen at a
10 !LM concentration was strictly due to non-specific damage
unrelated to enhancement of TGF-f3, production. As our
work demonstrates, the amount of TGF-f31 induced by
tamoxifen highly correlated with the amount of DNA
cleavage. In addition, tamoxifen induced DNA cleavage
was abrogated by the addition of an anti-TGF-f, antibody.
This demonstrates that TGF-fl, does have an important role
in tamoxifen-induced apoptosis in both ER-positive and ER-
negative cells.
We agree that current evidence suggests that tamoxifen
may act via a post-transcriptional mechanism at lower
concentrations and a transcriptional mechanism at higher
concentrations.
Whether such mechanistic differences are important in
determining the therapeutic effectiveness in vivo remain to be
determined.
Roger R Perry,
Yuan Kang,
Bridget Greaves,
Division of Surgical Oncology,
Eastern Virginia Medical School,
Norfolk, Virginia 23507, USA
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